The DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
Open accessAbstract
Owing to their potent glucose-lowering efficacy and substantial weight loss effects, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now considered part of the frontline therapeutic options to treat both type 2 diabetes mellitus and nondiabetic overweight/obesity. Stemming from successful demonstration of their cardiometabolic modulation and reduction of major adverse cardiovascular events in clinical outcome trials, GLP-1 RAs have since been validated as agents with compelling cardiovascular protective properties. Studies spanning from the bench to preclinical and large-scale randomised controlled trials have consistently corroborated the cardiovascular benefits of this pharmacological class. Most notably, there is converging evidence that they exert favourable effects on atherosclerotic ischaemic endpoints, with preclinical data indicating that they may do so by directly modifying the burden and composition of atherosclerotic plaques. This narrative review examines the underlying pharmacology and clinical evidence behind the cardiovascular benefits of GLP-1 RAs, with particular focus on atherosclerotic cardiovascular disease. It also delves into the mechanisms that underpin their putative plaque-modifying actions, addresses existing knowledge gaps and therapeutic challenges and looks to future developments in the field, including the use of combination incretin agents for diabetes and weight loss management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Cardiovascular outcome trials confirm reductions in major adverse cardiovascular events, and emerging evidence suggests benefits for renal function and inflammation (8, 24–29).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449 · cited 1×
“In 2019, it was estimated that of 523 million people affected by all-cause CVD worldwide, there were 197 million prevalent cases of coronary artery disease (CAD), resulting in 9 million deaths [2].”
BackgroundSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“T2DM currently affects 463 million people globally, a number predicted to increase by 25% in 2030 and 51% in 2045 [4].”
Background(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 4×
“Moreover, several have also achieved significant reductions compared to placebo in composite MACEs, usually comprising the endpoints of cardiovascular death, nonfatal myocardial infarction (MI) and nonfatal ischaemic stroke [50,54,56,57,59] (Table 2).”
BackgroundInfluentialIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 1×
“While better glycaemic control has long been associated with improved microvascular complications of T2DM, it has been more difficult to demonstrate this relationship for ASCVD (or macrovascular) outcomes [85].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 10×
“For example, in SUSTAIN-6 64% of participants were also taking aspirin, 21% clopidogrel or ticagrelor, 77% lipid-lowering medication (mostly statins) and 94% anti-hypertensives with 50% on ACE inhibitors [50].”
BackgroundMethodInfluentialEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“These include PCSK9 inhibitors (e.g., evolocumab [65]) and anti-inflammatory agents, such as colchicine [66].”
Background
Cited by
Sivaprasad, S., Wong, T. Y., Gardner, T. W., Sun, J. K., & Bressler, N. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00646-x · Cited by 77
HOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 70
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 48
Body image and interest in GLP-1 weight loss medications
Markey, C. N., August, K. J., Malik, D., & Richeson, A. L. (2025) · Body Image · doi:10.1016/j.bodyim.2025.101890 · Cited by 37
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Metadata
- Authors
- Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J.
- Affiliations
- Flinders University (AU)
- South Australian Health and Medical Research Institute (AU)
- The University of Adelaide (AU)
- Central Adelaide Local Health Network (AU)
- Corresponding author
- Psaltis, Peter J.
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2024-08-09
- Volume
- 13
- Issue
- 16
- Pages
- 4674
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC11355214
- OpenAlex
- W4401456648
- Semantic Scholar
- d60e5668490f218a02d74697c80196dd02a2d70d
- Cited by
- 66
- References
- 178
- Citations by year
- 2026: 32 · 2025: 31 · 2024: 3
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Heart Foundation of Australia (FLF106656)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, cardioprotection, atherosclerotic cardiovascular disease, type 2 diabetes, obesity, weight loss, incretin-based therapy, major adverse cardiovascular events, cardiometabolic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs. https://app.cochat.ai/papers/10.3390/jcm13164674
- The paper
- Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024). Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs. Journal of Clinical Medicine. https://doi.org/10.3390/jcm13164674
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.